Weihe Zhang Yujuan Jiao Jinsong Jiao Ming Jin Dantao Peng
10.3389/fimmu.2022.1047992
Front Immunol
2022 Dec 8;13:1047992.
case report hypogammaglobulinemia neuromyelitis optica spectrum disorder ofatumumab rituximab
CC BY
https://pubmed.ncbi.nlm.nih.gov/36569904/
Agammaglobulinemia / drug therapy Neuromyelitis Optica / drug therapy
Agammaglobulinemia / drug therapy Neuromyelitis Optica / drug therapy Case Reports Research Support, Non-U.S. Gov't Aged Female Genotype Humans Immunoglobulins, Intravenous / therapeutic use Immunologic Factors / therapeutic use Immunosuppressive Agents / therapeutic use Receptors, IgG Recurrence Rituximab / pharmacology Rituximab / therapeutic use Rituximab Immunoglobulins, Intravenous ofatumumab Immunologic Factors Immunosuppressive Agents FCGR3A protein, human Receptors, IgG
PMC9773878
36569904
Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: A case report
2022